Suppression of <i>F</i> <sub>ENO</sub> with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?

Faruqi, Shoaib; Zhou, Sean; Thompson, Joanne; Robinson, Terry; Watkins, Karen; Cummings, Helena; Jackson, Nicola; Prakash, Anoop; Crooks, Michael

Suppression of F _ENO with observed inhaled corticosteroid therapy in severe asthma: is it a useful test in clinical practice?

Faruqi, Shoaib; Zhou, Sean; Thompson, Joanne; Robinson, Terry; Watkins, Karen; Cummings, Helena; Jackson, Nicola; Prakash, Anoop; Crooks, Michael.

Afiliação

Faruqi S; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Zhou S; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Thompson J; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Robinson T; Harrogate and District NHS Foundation Trust, Respiratory, Harrogate, UK.
Watkins K; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Cummings H; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Jackson N; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Prakash A; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.
Crooks M; Castle Hill Hospital, Respiratory Medicine, Cottingham, UK.

ERJ Open Res ; 5(4)2019 Oct.

Article em En | MEDLINE | ID: mdl-31777751

RESUMO

F ENO suppression testing is practical and feasible during assessment for biologics in severe asthma. Patients with significant F ENO suppression were less likely to be recommended biologics but saw similar reductions in exacerbation frequency. http://bit.ly/35oSoxP.

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: ERJ Open Res Ano de publicação: 2019 Tipo de documento: Article